Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of “Buy” by Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average rating of “Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $209.1429.

Several research firms have recently weighed in on PVLA. HC Wainwright reissued a “buy” rating and set a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Stephens reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $152.59 on Tuesday. Palvella Therapeutics has a fifty-two week low of $49.81 and a fifty-two week high of $161.38. The business has a 50-day simple moving average of $146.69 and a two-hundred day simple moving average of $127.75. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -31.59 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35). As a group, research analysts predict that Palvella Therapeutics will post -6.36 earnings per share for the current year.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $327,860.34. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PVLA. Millennium Management LLC bought a new stake in shares of Palvella Therapeutics during the 1st quarter valued at about $7,553,000. Goldman Sachs Group Inc. bought a new position in shares of Palvella Therapeutics in the 1st quarter worth approximately $533,000. Geode Capital Management LLC lifted its stake in shares of Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after purchasing an additional 79,787 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Palvella Therapeutics in the second quarter worth approximately $224,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.